InsidersTradesSigma
Follow the 华恒生物 share price and the full directors' dealings record of the company, a listed issuer based in China. Shares trade on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 华恒生物 has published 1 public disclosures. Market capitalisation: €4bn. The latest transaction was disclosed on 6 June 2025 (Sale). Among the most active insiders: 唐思青. Every trade is openly available.
1
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€268,366
1 ops.
Sell Volume
2Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,993 of 28,857 companies
33.6
score / 100
Value34
Quality34
FCF yld-13%
Earn yld3.3%
EV/EBITDA15.9x
ROE4.3%
Gross mgn21%
Net mgn4.6%
Debt/EBITDA5.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 June 2025
About 华恒生物
华恒生物 is a company in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and production of biological and pharmaceutical products.